Atlas Trials

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

Clinical trial NCT01094405 · COMPLETED

Trial details

NCT number
NCT01094405
Sponsor
Chinese University of Hong Kong
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal CancerEpstein-Barr Virus Infections
Start date
2010-03-31
Primary completion
2020-08-27
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.